

## Levothyroxine Sodium - (100 mcg/vial and 500 mcg/vial)

<b>Generic Name</b>	Levothyroxine sodium	<b>Innovator</b>	Fresenius Kabi
<b>Dosage</b>	100 mcg/vial and 500 mcg/vial	<b>Branded US Sales</b>	Less Than \$1000 mn
<b>Probable FTF</b>	Less Than 5	<b>Known Para IV Filers</b>	More Than 5
<b>Other ANDA developers</b>	Less Than 5	<b>Tentative Approvals</b>	None
<b>Final Approvals</b>	More Than 5	<b>Generic Launches</b>	Less Than 5
<b>Indication</b>	Indicated for the treatment of myxedema coma		
<b>Complexities</b>	Yes		

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

## Levothyroxine Sodium - (200mcg/vial)

<b>Generic Name</b>	Levothyroxine sodium	<b>Innovator</b>	Fresenius Kabi
<b>Dosage</b>	200mcg/vial	<b>Branded US Sales</b>	Less Than \$1000 mn
<b>Probable FTF</b>	Less Than 5	<b>Known Para IV Filers</b>	Less Than 5
<b>Other ANDA developers</b>	Less Than 5	<b>Tentative Approvals</b>	None
<b>Final Approvals</b>	Less Than 5	<b>Generic Launches</b>	Less Than 5
<b>Indication</b>	Indicated for the treatment of myxedema coma		
<b>Complexities</b>	Yes		

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

## Levothyroxine Sodium - (100 mcg/5 mL (20 mcg/mL), 200 mcg/5 mL (40 mcg/mL), and 500 mcg/5 mL (100 mcg/mL) ; Solution, Intravenous)

<b>Generic Name</b>	Levothyroxine sodium	<b>Innovator</b>	Fresenius Kabi
<b>Dosage</b>	100 mcg/5 mL (20 mcg/mL), 200 mcg/5 mL (40 mcg/mL), and 500 mcg/5 mL (100 mcg/mL) ; Solution, Intravenous	<b>Branded US Sales</b>	Less Than \$1000 mn
<b>Probable FTF</b>	None	<b>Known Para IV Filers</b>	Less Than 5
<b>Other ANDA developers</b>	Less Than 5	<b>Tentative Approvals</b>	None
<b>Final Approvals</b>	None	<b>Generic Launches</b>	None
<b>Indication</b>	Levothyroxine Sodium Injection is L-thyroxine (T4) indicated in adult patients for the treatment of myxedema coma.		
<b>Complexities</b>	Yes		

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

## Levothyroxine Sodium - (0.1MG/1ML ; Solution)

<b>Generic Name</b>	Levothyroxine sodium	<b>Innovator</b>	Hikma
<b>Dosage</b>	0.1MG/1ML ; Solution	<b>Branded US Sales</b>	Less Than \$1000 mn
<b>Probable FTF</b>	None	<b>Known Para IV Filers</b>	None
<b>Other ANDA developers</b>	Less Than 5	<b>Tentative Approvals</b>	None
<b>Final Approvals</b>	None	<b>Generic Launches</b>	None
<b>Indication</b>	Levothyroxine Sodium is an L-thyroxine product. Levothyroxine (T4) Sodium Injection is indicated for the treatment of myxedema coma. (		
<b>Complexities</b>	Yes		

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Executive Summary

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Patent Status

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Launch Timelines and Competition

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.

### Chronology Of Events

Please Contact [contact@researchdelta.com](mailto:contact@researchdelta.com) to get Detailed Information.